William C. Wright
St. Jude Children's Research Hospital
22 Papers
5 Citations
William C. Wright is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 7, co-authored 14 publications. Previous affiliations of William C. Wright include University of Tennessee Health Science Center.
Chat about Author
Papers
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.
Ogheneochukome Lolodi,Yue-Ming Wang,William C. Wright,William C. Wright,Taosheng Chen,Taosheng Chen +5 more
TL;DR: Intense research is ongoing to understand the functional ramifications of aberrant expression of parts of the xenobiotic response system in diseased states with the goal of designing novel drugs that can selectively target them.
71
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.
Min Pan,William C. Wright,Richard H. Chapple,Asif Zubair,Manbir Sandhu,Jake E. Batchelder,Brandt C. Huddle,Jonathan Low,Kaley Blankenship,Yingzhe Wang,Brittney Gordon,Payton Archer,Samuel W. Brady,Sivaraman Natarajan,Matthew J. Posgai,John D. Schuetz,Darcie J. Miller,Ravi C. Kalathur,Siquan Chen,Jon P. Connelly,M. Madan Babu,Michael A. Dyer,Michael A. Dyer,Shondra M. Pruett-Miller,Burgess B. Freeman,Taosheng Chen,Lucy A. Godley,Scott C. Blanchard,Elizabeth Stewart,John Easton,Paul Geeleher +30 more
TL;DR: In this article, the small molecule CX-5461 was identified as selectively cytotoxic to high-risk neuroblastoma and synergistic with low picomolar concentrations of topoisomerase I inhibitors.
50
Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer.
TL;DR: Significant progress has been made in recent years, suggesting that it is feasible to develop selective PXR antagonists, and the strategies are based on the molecular mechanisms of antagonism in related NRs that can be applied to the design of PXr antagonists, primarily driven by structural information.
40
Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
William C. Wright,Jude Chenge,Jingheng Wang,Hazel M. Girvan,Lei Yang,Sergio C. Chai,Andrew D. Huber,Jing Wu,Peter Oladimeji,Andrew W. Munro,Taosheng Chen +10 more
TL;DR: The results provide a structural basis for selective CYP3A5 inhibition, along with mechanistic insights, and highlight clobetasol as an important chemical tool for target validation.
39
Discovery and Characterization of the Antimetabolite Action of Thioacetamide-Linked 1,2,3-Triazoles as Disruptors of Cysteine Biosynthesis in Gram-Negative Bacteria
Miranda J. Wallace,Miranda J. Wallace,Suresh Dharuman,Dinesh M. Fernando,Stephanie M. Reeve,Clifford T. Gee,Jiangwei Yao,Elizabeth C. Griffith,Gregory A. Phelps,William C. Wright,John M Elmore,Robin B. Lee,Taosheng Chen,Richard E. Lee +13 more
TL;DR: The potential of antimetabolite drug discovery as a promising approach to the discovery of novel GN antibiotics, and the pharmacological promise of TAT CysK probes are highlighted.
21